NYSE · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · LARGE CAP
Mckesson Corp. MCK
19 fiscal years on record · USD · FY2025 reported · SEC filings only
13 YEARS OF DIVIDEND GROWTH
In brief
What this company does
Written from the business description in MCKESSON CORP's annual report to the U.S. Securities and Exchange Commission, filed 8 May 2026. Every sentence was checked against that document before publication.
Growth
USD 403.4B
Revenue, FY2025 · full 19-year series below
Revenue $B
Net income $B
FY2025 · Revenue 403.4 · Net income 4.8
Compound annual growth
+13.4%
+11.1%
+7.8%
+8.9%
+10.2%
+7.7%
+9.6%
+15.3%
+14.7%
+15.2%
+14.9%
+13.7%
+11.4%
+10.4%
+9.3%
+38.2%
+10.7%
+7.0%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at +11.1% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
1 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 1.5% · Net 1.3%
ROE
FY2020 · ROE -179.0%
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 403.4 | 359.1 | 309.0 | 276.7 | 264.0 | 238.2 | 231.1 | 214.3 | 208.4 | 198.5 | 190.9 | 179.0 | 137.4 | 122.2 | 122.3 | 112.1 | 108.7 | 106.6 | 101.7 |
| Operating income $B | 6.2 | 4.4 | 3.9 | 4.4 | 2.0 | −5.0 | 2.5 | 0.9 | 0.8 | 7.1 | 3.5 | 3.0 | 2.4 | 2.3 | 2.1 | 1.8 | 2.0 | 1.2 | 1.5 |
| EBITDA $B | 6.5 | 4.7 | 4.2 | 4.7 | 2.4 | −4.7 | 2.8 | 1.2 | 1.1 | 7.4 | 3.8 | 3.3 | 2.6 | 2.5 | 2.3 | 2.0 | 2.2 | 1.3 | 1.6 |
| Income tax $B | 1.1 | 0.9 | 0.6 | 0.9 | 0.6 | −0.7 | 0.0 | 0.4 | −0.1 | 1.6 | 0.9 | 0.8 | 0.8 | 0.6 | 0.5 | 0.5 | 0.6 | 0.2 | 0.5 |
| Net income $B | 4.8 | 3.3 | 3.0 | 3.6 | 1.1 | −4.5 | 0.9 | 0.0 | 0.1 | 5.1 | 2.3 | 1.5 | 1.3 | 1.3 | 1.4 | 1.2 | 1.3 | 0.8 | 1.0 |
| Free cash flow $B | 5.7 | 5.5 | 3.9 | 4.8 | 4.0 | 4.1 | 4.0 | 3.6 | 3.9 | 4.3 | 3.2 | 2.7 | 2.9 | 2.2 | 2.7 | 2.1 | 2.1 | 1.2 | 0.7 |
| EPS, diluted $ | 38.38 | 25.72 | 22.39 | 25.03 | 7.23 | −28.26 | 4.95 | 0.17 | 0.32 | 22.73 | 9.70 | 6.27 | 5.41 | 5.59 | 5.59 | 4.57 | 4.62 | 2.95 | 3.32 |
| Dividend / sh $ | 3.17 | 2.75 | 2.40 | 2.09 | 1.83 | 1.67 | 1.62 | 1.51 | 1.30 | 1.12 | 1.08 | 0.96 | 0.92 | 0.80 | 0.80 | 0.72 | 0.48 | 0.48 | 0.24 |
| Payout % | 8 | 10 | 10 | 8 | 25 | −6 | 33 | 859 | 391 | 5 | 11 | 15 | 17 | 14 | 14 | 14 | 10 | 14 | 7 |
| ROE % | · | · | · | · | · | −179.0 | 13.7 | 0.4 | 0.6 | 50.7 | 26.7 | 17.9 | 16.2 | 19.3 | 20.0 | 16.3 | 18.4 | 13.3 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Compare
This company against its peers
Mckesson Corp.vsCencora, Inc.Same industry: Wholesale-Drugs, Proprietaries & Druggists' SundriesMckesson Corp.vsCardinal Health Inc.Same industry: Wholesale-Drugs, Proprietaries & Druggists' SundriesMckesson Corp.vsHerbalife Ltd.Same industry: Wholesale-Drugs, Proprietaries & Druggists' SundriesMckesson Corp.vsNU Skin Enterprises, Inc.Same industry: Wholesale-Drugs, Proprietaries & Druggists' SundriesMckesson Corp.vsCosmos Health Inc.Same industry: Wholesale-Drugs, Proprietaries & Druggists' SundriesMckesson Corp.vsCellyan Biotechnology Co. Ltd.Same industry: Wholesale-Drugs, Proprietaries & Druggists' SundriesMckesson Corp.vsStemtech Corp.Same industry: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Provenance
Company facts, as filed
How we verify · 0 failures in 93 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years. 2 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityWholesale-Drugs, Proprietaries & Druggists' Sundries
Listed onNYSE
Incorporated inDelaware
Fiscal year endsMarch 31
Data on record since2007